Search

Displaying results 3641 - 3650 of 10000 in total
  1. Drug

    Bioallethrin

    go.drugbank.com/drugs/DB13746
    ApprovedWithdrawn

    A mixture of the two same stereoisomers, but in an approximate ratio of R:S in 1:3, is called esbiothrin. … It is claimed to have low mammalian toxicity.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Teplizumab

    go.drugbank.com/drugs/DB06606
    ApprovedInvestigational

    [A241490] Anti-CD3 therapy has traditionally been used to prevent graft-versus-host-disease in organ transplantation but more recently has been explored to prolong the onset of (T1D) in high-risk patients … [L44091] Fc-receptors can bind to the "tail-end" anti-CD3 antibodies in an antigen-non-specific manner and lead to severe adverse effects related to cytokine release syndrome (CRS).

  3. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    Seladelpar works to block bile acid synthesis.[A264234] … [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  4. Drug

    19-norandrostenedione

    go.drugbank.com/drugs/DB01434
    ExperimentalIllicit

    19-Norandrostenedione refers to two steroid isomers that were once marketed as dietary supplements and mainly used by body builders. … After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency.

  5. Drug

    Dofetilide

    go.drugbank.com/drugs/DB00204
    ApprovedInvestigational

    Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation … and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Influenza A virus A/Brisbane/02/2018 (H1N1) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB15517
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

    Mixtures: FluQuadri Quadrivalent Influenza Vaccine, 0.25 ml, FluQuadri Quadrivalent Influenza Vaccine, 0.5 ml
  7. Drug

    Ensartinib

    go.drugbank.com/drugs/DB14860
    ApprovedInvestigational

    [A265030] The drug is 10-fold more potent in the inhibition of the growth of ALK-positive lung cancer cell lines when compared to [crizotinib]. … when compared to [crizotinib].

  8. Drug

    SynKIR-110

    go.drugbank.com/drugs/DB17365
    Investigational

    SynKIR-110 are autologous T cells genetically engineered to express an anti-mesothelin killer immunoglobulin-like receptor-chimeric antigen receptor (KIR-CAR).

    Synonyms: SynKIR-110, SynKIR-meso CAR-T cells
  9. Drug

    CA-170

    go.drugbank.com/drugs/DB15772
    Investigational

    CA-170 is a selective, small molecule inhibitor of PD-L1.

  10. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the